LY6G6D

Across TCGA pan-cancer cohorts, LY6G6D RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated LY6G6D data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LY6G6D RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LY6G6D expression acts as an unfavorable survival marker, although some lineages such as SCLC and COAD show a favorable association.

LUAD, SCLC, and LGG are the cancer types where LY6G6D RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	IV	0.359	0.814	<.001	78	view →
SCLC	DFS	Quartile	II,III,IV	0.685	0.187	.004	53	view →
LGG	DFS	Median	All	0.660	0.812	<.001	46	view →
ACC	DFS	Tertile	All	0.193	0.659	.004	36	view →
BLCA	DFS	Tertile	II,III,IV	0.260	0.384	.006	26	view →
KIRC	OS	Tertile	All	0.783	0.889	.009	24	view →
COAD	OS	Median	IV	0.791	0.498	.003	22	view →
PAAD	DFS	Tertile	All	0.360	0.506	.024	18	view →
CHOL	OS	Tertile	III,IV	0.275	0.886	.045	18	view →
LUSC	DFS	Quartile	III,IV	0.166	0.849	<.001	18	view →
LIHC	DFS	Tertile	All	0.251	0.566	.001	12	view →
PCPG	OS	Tertile	All	0.773	1.000	.004	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

LY6G6D–LUAD (DFS)

Open the LUAD breakdown →